Maruti Suzuki Clocks Record Sales In FY25 Amid Muted India Sales, Surging Exports
Sales of Maruti Suzuki India Ltd. rose to a record high in fiscal 2025, but that masked muted demand at home amid surge in exports.
Total sales of India's largest carmaker rose 4.63% to 22,34,266 units in the fiscal ended March 31, 2025, as against 21,35,323 units in FY24, according to an exchange filing. That includes highest ever annual domestic sales of 1,795,259 units and highest ever annual exports of 3,32,585 units.
But year-on-year, local car sales rose by less than 1,000 units even as the exports surged by nearly 50,000 units. The domestic scenario doesn't improve much even after Super Carry and sales to Toyota India were included in the mix.
Key Highlights
Domestic PV sales up 0.05% at 17,60,767 units.
Total India sales up 2.66% YoY at 19,01,681 units.
Exports up 17.49% YoY at 3,32,585 units.
The muted sales at home can be attributed to lack of demand for small cars, hatchbacks and sedans, even as Maruti Suzuki's SUVs play catch-up with rival offerings from Mahindra & Mahindra Ltd.
Sales of Maruti Suzuki's passenger cars — including Alto, S-Presso, Baleno, Celerio, Dzire, Ignis, Swift, WagonR and Ciaz — fell 7.7% year-on-year to 9,04,909 units as against 9,80,446 units in FY24.
Over the same time, Maruti Suzuki's SUVs — Brezza, Ertiga, Fronx, Grand Vitara, Invicto, Jimny, XL6—rose 12.12% year-on-year to 7,20,186 units.
But that performance pales in comparison to that of M&M.
India's largest SUV maker by revenue sold 5,51,487 units in FY25 as against 4,59,864 units in FY24, clocking a growth of 20% year-on-year. That growth came on the back of the launch of the XUV 3XO compact SUV, as well as the Thar Roxx. Maruti Suzuki, meanwhile, didn't have a new SUV last year.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets